Arrowhead has not initiated research coverage on Bone Therapeutics yet.

About
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage...
Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy and an innovative biological product in later-stage clinical development across a number of disease areas, which target markets with large unmet medical needs and limited innovation. Bone Therapeutics’ core technology is based on its allogeneic cell therapy platform (ALLOB) which uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, cutting-edge manufacturing process. The Company’s ALLOB product pipeline includes a cell therapy product candidate that is expected to enter Phase IIb clinical development for the treatment of difficult-to-heal fractures and a Phase II asset in patients undergoing a spinal fusion procedure. In addition, the Company is also developing an off-the-shelf protein solution, JTA-004, which is expected to enter Phase III development for the treatment of pain in knee osteoarthritis. Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. Further information is available at www.bonetherapeutics.com.
  • 9
    Dec
    19
    News Release
    Transparency notification received from S.R.I.W. SA and Sofipôle SA
  • 29
    Nov
    19
    News Release
    Information on the total number of voting rights and shares
  • 25
    Nov
    19
    News Release
    The preliminary documents for the Extraordinary General Shareholder Meeting on 12 December 2019 have been made available
  • 6
    Nov
    19
    News Release
    Bone Therapeutics Reports Financial Results for the First Nine Months of 2019 and Provides Third Quarter 2019 Business Update
  • 31
    Oct
    19
    Company Presentation
    Company Presentation
  • 2
    Oct
    19
    News Release
    Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27 th Annual Meeting of the European Orthopaedic Research Society
  • 27
    Sep
    19
    News Release
    Bone Therapeutics to present data from its Phase II/III trial with JTA-004 at the 2nd World Congress on Rheumatology & Orthopedics
  • 30
    Aug
    19
    Corporate Update
    Interim Financial Report H1 2019
  • 30
    Aug
    19
    Company Presentation
    H1 2019 Results
  • 30
    Aug
    19
    News Release
    Bone Therapeutics reports half year 2019 results
  • 13
    Jun
    19
    News Release
    Bone Therapeutics’ allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase IIa study in patients undergoing a lumbar spinal fusion procedure
  • 12
    Jun
    19
    News Release
    Bone Therapeutics announces results of Annual General Meeting
  • 24
    May
    19
    News Release
    Bone Therapeutics to present data at TERMIS European Chapter Meeting 2019
  • 7
    May
    19
    News Release
    Bone Therapeutics Provides First Quarter 2019 Business Update
  • 25
    Apr
    19
    Corporate Update
    Annual Report 2018
  • 25
    Apr
    19
    Corporate Update
    Business Overview 2018
  • 12
    Mar
    19
    News Release
    Bone Therapeutics appoints Olivier Godeaux as Chief Medical Officer and Benoit Moreaux as Chief Scientific and Technology Officer
  • 1
    Mar
    19
    Company Presentation
    Annual Results 2018
  • 1
    Mar
    19
    News Release
    Bone Therapeutics announces 2018 full year results
  • 22
    Jan
    19
    News Release
    Bone Therapeutics announces 2019 business outlook and reports year-end 2018 cash position
  • 30
    Aug
    18
    Corporate Update
    Interim Financial Report H1 2018
  • 25
    Apr
    17
    Corporate Update
    Business Overview 2018